Samsung Biologics CEO John Lim “Leap as a global bio company through intensive investment”

Samsung Biologics CEO John Lim speaks at the general shareholders’ meeting. Source = Samsung Biologics

John Lim, CEO of Samsung Biologics (207940), emphasized that this year’s investment will make it a global bio company.

Samsung Biologics held the 11th regular general meeting of shareholders at Incheon Global Campus located in Yeonsu-gu, Incheon on the 29th.

At this general meeting of shareholders, a total of five agenda items were proposed and approved, including △approval of financial statements, △appointment of directors, △appointment of outside directors who become audit committee members, △appointment of audit committee members, and △approval of limits on director remuneration.

Park Jae-wan, chairman of the Korean Peninsula Advancement Foundation, and Lee Chang-woo, a professor of business administration at Seoul National University, were newly appointed as outside directors. Independent director Heo Geun-nyeong and inside director Kim Dong-joong were re-appointed.

The general shareholders’ meeting was held electronically through the website as in last year. Electronic voting was held for a total of 10 days from the 19th to the 28th through the Korea Securities Depository (K-VOTE). It allows shareholders to exercise their voting rights on each agenda item in advance without attending the shareholders’ meeting in person. For shareholders who could not participate in the shareholders’ meeting in person, an online live broadcast was also conducted.

John Lim, CEO of Samsung Biologics, said, “Samsung Biologics will make a full-fledged leap into a global comprehensive bio company through intensive investment in portfolio expansion, human resource training, and process innovation. We will do our best to increase corporate value while taking on challenges.”

Send articles on social media



Leave a Comment